| ln Vitro |
DSPE-PEG-CMP-EXO (20 μM miR302 mimic; 30 min loading and incubation, 0-72 h stability test, 1-48 h release quantification) can effectively encapsulate 20 μM miR302 mimic, protect miR302 in serum-containing medium for up to 24 h, and achieve 90% cumulative release of miR302 within 48 h [2]. DSPE-PEG-CMP-miR302-EXO (6 h hypoxia, 16 h reperfusion) significantly upregulated miR302 expression, increased Ki67 and Yap protein levels, and enhanced the proliferation of H9C2 cardiomyocytes after in vitro ischemia/reperfusion injury [2].
|
|---|---|
| ln Vivo |
DSPE-PEG-CMP alone (0.25 μg per mouse; intravenous injection; once every 2 days; 4 weeks) did not significantly reduce myocardial I/R damage, reduce apoptosis and inflammation, or improve cardiac function in male C57BL/6 mice [2].
|
| Animal Protocol |
Animal/Disease Models:C57BL/6 (male, 8-10 weeks old, 20-25 g, reperfusion performed 60 minutes after ligation of the left anterior descending coronary artery) [2]
Doses: 0.25 μg (DSPE-PEG-CMP) per mouse. Route of Administration: Intravenous injection; once every 2 days; for 4 weeks. Experimental Results: Compared with the model group, serum levels of myocardial injury markers (cTnI, CKMB) and pro-inflammatory factors (TNF-α, IL-1β) showed little or no significant improvement. Compared with the model group, there was no significant reduction in cardiomyocyte necrosis, structural disorder, or cardiomyocyte apoptosis rate. Compared with the model group, there were no significant improvements in left ventricular ejection fraction (EF), fractional shortening (FS), left ventricular mass index, left ventricular end-diastolic diameter (LVAWd), left ventricular end-diastolic diameter (LVAWs), left ventricular end-diastolic diameter (LVVOLd), left ventricular end-diastolic diameter (LVVOLs), left ventricular end-diastolic diameter (LVIDd), left ventricular end-diastolic diameter (LVIDs), left ventricular posterior wall end-diastolic diameter (LVPWd), or left ventricular posterior wall end-diastolic diameter (LVPWs). |
| References |
|
| Appearance |
White to off-white solid
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
